Research programme: extracellular drug conjugates - Centrose

Drug Profile

Research programme: extracellular drug conjugates - Centrose

Latest Information Update: 28 Jul 2016

Price : $50

At a glance

  • Originator Wisconsin Alumni Research Foundation
  • Developer Centrose; University of Wisconsin System
  • Class Cardiac glycosides; Drug conjugates; Monoclonal antibodies; Small molecules
  • Mechanism of Action
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity No

Highest Development Phases

  • No development reported Colorectal cancer; Non-small cell lung cancer

Most Recent Events

  • 28 Jul 2016 No recent reports on development identified - Preclinical for Colorectal cancer and Non-small cell lung cancer in USA (Transdermal)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top